Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Debt (2016 - 2025)

Historic Total Debt for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $1.7 billion.

  • Integra Lifesciences Holdings' Total Debt rose 251.46% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 251.46%. This contributed to the annual value of $1.7 billion for FY2024, which is 9772.63% up from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Total Debt stood at $1.7 billion, which was up 251.46% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Total Debt peaked at $1.7 billion during Q3 2025, and registered a low of $769.1 million during Q1 2023.
  • Its 5-year average for Total Debt is $1.1 billion, with a median of $870.3 million in 2022.
  • Per our database at Business Quant, Integra Lifesciences Holdings' Total Debt crashed by 1476.18% in 2021 and then skyrocketed by 9827.65% in 2024.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Total Debt stood at $869.3 million in 2021, then fell by 11.27% to $771.3 million in 2022, then grew by 8.92% to $840.1 million in 2023, then skyrocketed by 97.73% to $1.7 billion in 2024, then rose by 5.21% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.7 billion during Q1 2025.